• Collaboration leads to new antibody media
    New antibody media for affinity chromatography has been created by two firms in the industry

Solid Phase Extraction (SPE)

Collaboration leads to new antibody media

Aug 17 2010

Collaboration between antibody-based affinity purification technology provider BAC BV and human proteins provider Octapharma has led to the development of a new affinity ligand for purifying human cell cultures.

G-CSF CaptureSelect is licensed to Octapharma for use in purifying recombinant human granulocyte-colony stimulating factor, or G-CSF.

Kim Bjornstrup, vice-chairman of Octapharma, explains that the two companies' previous work led to the development.

"The start of this collaboration with BAC, in G-CSF, came from the success with our previous collaboration to develop a ligand for the purification of factor IX," the spokesman says.

With the ligand, Octapharma aims to cut the downstream development time needed in order to produce the recombinant protein, as well as raising the overall recovery of the process compared with conventional techniques.

Octapharma was founded in 1983 and has grown to employ more than 4,000 people, with sales in 2009 surpassing the €1 billion (£820 million) benchmark.

Digital Edition

Chromatography Today - Buyers' Guide 2022

December 2021

In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


ASMS Conference

Jun 04 2023 Houston, TX, USA

Plastics Recycling World Expo Europe

Jun 14 2023 Essen, Germany

HPLC 2023

Jun 18 2023 Dusseldorf, Germany


Jul 04 2023 Cardiff, UK

Water Expo Nigeria 2023

Jul 11 2023 Lagos, Nigeria

View all events